Intuitive Surgical (NASDAQ:ISRG – Get Free Report)‘s stock had its “buy” rating reissued by equities researchers at BTIG Research in a report released on Wednesday, Benzinga reports. They presently have a $454.00 price objective on the medical equipment provider’s stock. BTIG Research‘s price objective would suggest a potential upside of 0.04% from the company’s current price.
ISRG has been the subject of several other research reports. Oppenheimer reiterated an “outperform” rating and issued a $500.00 price objective on shares of Intuitive Surgical in a research report on Wednesday. Weiss Ratings restated a “hold (c)” rating on shares of Intuitive Surgical in a report on Friday, August 14th. Sanford C. Bernstein restated an “outperform” rating on shares of Intuitive Surgical in a report on Wednesday, August 12th. Erste Group Bank upgraded Intuitive Surgical from a “hold” rating to a “buy” rating in a report on Wednesday. Finally, UBS Group restated a “buy” rating on shares of Intuitive Surgical in a report on Tuesday, October 13th. Twenty-four research analysts have rated the stock with a Buy rating, six have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $495.71.
Intuitive Surgical Stock Up 2.2%
Intuitive Surgical (NASDAQ:ISRG – Get Free Report) last posted its earnings results on Tuesday, October 20th. The medical equipment provider reported $3.00 EPS for the quarter, topping the consensus estimate of $2.65 by $0.35. The business had revenue of $3.05 billion during the quarter, compared to the consensus estimate of $2.91 billion. Intuitive Surgical had a return on equity of 18.17% and a net margin of 25.54%. Intuitive Surgical’s revenue was up 21.7% on a year-over-year basis. During the same quarter last year, the company earned $2.40 EPS. Sell-side analysts forecast that Intuitive Surgical will post 8.87 earnings per share for the current fiscal year.
Insider Activity at Intuitive Surgical
In other news, VP Fredrik Widman sold 1,089 shares of the company’s stock in a transaction dated Tuesday, September 15th. The stock was sold at an average price of $374.44, for a total transaction of $407,765.16. Following the completion of the transaction, the vice president directly owned 1,026 shares of the company’s stock, valued at $384,175.44. This represents a 51.49% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Mark Brosius sold 77 shares of the company’s stock in a transaction dated Friday, August 21st. The stock was sold at an average price of $375.57, for a total value of $28,918.89. Following the sale, the executive vice president owned 881 shares in the company, valued at $330,877.17. The trade was a 8.04% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 12,370 shares of company stock valued at $4,891,989 over the last ninety days. Company insiders own 0.60% of the company’s stock.
Institutional Trading of Intuitive Surgical
Several institutional investors and hedge funds have recently bought and sold shares of the business. Gibbs Wealth Management raised its stake in Intuitive Surgical by 20.8% in the third quarter. Gibbs Wealth Management now owns 4,761 shares of the medical equipment provider’s stock valued at $1,936,000 after buying an additional 821 shares during the period. Beaumont Financial Advisors LLC increased its stake in Intuitive Surgical by 3.8% during the 3rd quarter. Beaumont Financial Advisors LLC now owns 627 shares of the medical equipment provider’s stock worth $255,000 after acquiring an additional 23 shares during the period. Wedbush Securities Inc. increased its stake in Intuitive Surgical by 2.1% during the 3rd quarter. Wedbush Securities Inc. now owns 14,877 shares of the medical equipment provider’s stock worth $6,049,000 after acquiring an additional 304 shares during the period. WASHINGTON TRUST Co boosted its holdings in shares of Intuitive Surgical by 2.4% in the 3rd quarter. WASHINGTON TRUST Co now owns 43,013 shares of the medical equipment provider’s stock valued at $17,490,000 after purchasing an additional 997 shares in the last quarter. Finally, Washington Trust Advisors Inc. boosted its holdings in shares of Intuitive Surgical by 35.0% in the 3rd quarter. Washington Trust Advisors Inc. now owns 22,718 shares of the medical equipment provider’s stock valued at $9,238,000 after purchasing an additional 5,887 shares in the last quarter. Institutional investors own 83.64% of the company’s stock.
Key Headlines Impacting Intuitive Surgical
Here are the key news stories impacting Intuitive Surgical this week:
- Positive Sentiment: ISRG added to the Zacks Rank #1 (Strong Buy) list, reflecting expectations for continued earnings and business momentum. New Strong Buy Stocks for October 23rd
- Positive Sentiment: BTIG reaffirmed a Buy rating, Erste Group upgraded the stock to Buy, and Robert W. Baird raised its price target. Stifel Nicolaus, Oppenheimer and Piper Sandler also maintained Buy ratings. Erste Group Upgrades Intuitive Surgical
- Positive Sentiment: Third-quarter revenue increased approximately 21% year over year, supported by strong da Vinci system placements, a 15% increase in procedure volume and international growth. Earnings and revenue exceeded consensus expectations, while full-year guidance remained firm. Intuitive Surgical Stock: Margin Hit Masks Strong Q3 Growth Story
- Neutral Sentiment: JPMorgan raised its price target from $450 to $475 and kept an Overweight rating, while Bank of America reiterated Buy with a $470 target. These targets indicate continued confidence but only moderate upside from the current level. Intuitive Surgical Strong Q3 Beat
- Negative Sentiment: Shares gapped down after analysts highlighted a $450 million antitrust settlement, pricing-related charges and weaker margins. The settlement and pricing changes obscured otherwise strong operating growth. Intuitive Surgical Reports Q3 2026 Earnings
- Negative Sentiment: Investors are concerned that instrument price reductions, expected to reduce procedure revenue by roughly 3% to 5%, could slow 2027 procedure momentum and U.S. growth. RBC lowered its expectations, adding to the cautious reaction. Intuitive Surgical to Face Potential Risks in 2027
About Intuitive Surgical
Intuitive Surgical, Inc develops and manufactures robotic-assisted systems and related technologies for minimally invasive surgery. Its products are designed to help surgeons perform procedures through small incisions while providing enhanced visualization, precision and control. The company’s primary platform is the da Vinci Surgical System, which is used across a range of specialties, including urology, gynecology, general surgery, cardiothoracic surgery and other procedures.
The company also offers the Ion endoluminal system, which is designed to support minimally invasive lung biopsy procedures.
Featured Stories
- Five stocks we like better than Intuitive Surgical
- Capital One Earnings: After a Double Beat the Rally Is On
- Tractor Supply’s Q3 Beat Plants the Seeds for a Stock Rebound
- WD-40 Could Reward Patient Investors—Here’s Why
- NextEra and Dominion Have a Deal—Now Comes the Hard Part
Receive News & Ratings for Intuitive Surgical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intuitive Surgical and related companies with MarketBeat.com's FREE daily email newsletter.
